On October 3, 2026, TechCrunch reported that Neko Health, the body scan startup co-founded by Spotify’s Daniel Ek and Hjalmar Nilsonne, officially landed in New York City. The company has raised nearly $1 billion to date, including a $700 million round in July 2026. It already has a global waitlist of over 300,000 people. And it charges $500 for a one-hour scan that covers blood, skin, metabolism, and 55 biomarkers analyzed by AI-powered computer vision.
There is no insurance coverage. There is no referral required. You just show up, pay $500, and leave with data about your own body that most people never get from a doctor.
That is the business. And it is working.
What This Actually Means
Preventive healthcare in the United States is broken in a very specific, exploitable way: people know they should get checked out, but the cost and friction make it easy to avoid. Neko Health built a premium product that removes the friction entirely and prices it just below the “I need to think about this” threshold for high-income earners.
The contrarian move here is that Neko is not trying to replace insurance. It is not fighting the system. It is charging directly for something people actually want, keeping the price clean and the experience frictionless, and scaling by demand rather than by negotiating with payers. For a company in one of the most regulated industries in the world, that is a surprisingly lean business model.
Farooq Abbasi of Preface Ventures, an early investor who has been scanned twice, put it plainly: “I think preventative care and healthcare should be cheap and accessible.” That is the thesis. The question every entrepreneur should ask right now: what is the $500-a-session version of your industry’s most broken, most-avoided service?
The Numbers Behind It
The numbers from the article make the scale clear. Neko Health has raised close to $1 billion total, the majority of it in a single $700 million round in July 2026, before the company had even opened a U.S. location. That is a bet on demand, not a bet on revenue that already exists. The waitlist at 300,000 people across global markets is the proof point investors were buying.
At $500 per scan, even modest conversion from that waitlist is significant unit economics. If 10% of 300,000 waitlisted users complete one scan in year one, that is $15 million in direct revenue from a list that cost nothing to build. The real leverage is in the AI layer: Abbasi noted that in one of his scans, the biomarker count went from 15 to 55. As the data gets richer, the product improves without proportional cost increases. That is the compounding curve that makes investors willing to write nine-figure checks.
The Hustler’s Library Take
Here is the part most startup coverage misses: Neko Health is not really a health company. It is a data product with a health front-end and a premium positioning strategy. The scan is the entry point. The biomarker history, the year-over-year comparison, the AI-generated insight layer, that is the actual moat. A customer who scans once is a user. A customer who scans every year for a decade is an asset.
The business lesson is not “build a health startup.” It is this: the startups that command the biggest valuations right now are the ones creating proprietary data loops. Neko does not just give you a scan result. It builds a longitudinal record of your body that gets more valuable the longer you stay. What is the equivalent in your business? What would make your customers harder to leave, not because of a contract, but because of value that accumulates over time?
There is also a pricing lesson embedded here. Neko Health charges $500 and does not apologize for it. It is not covered by insurance and they do not lobby for that to change. They built for the segment of the market that will pay out of pocket for something genuinely useful. The founders who move fastest are usually the ones who stop trying to win on price and start competing on clarity of value.
What You Should Do
Map your waitlist equivalent. Neko’s 300,000-person waitlist was built before U.S. launch. If you do not have a mechanism to capture demand before you can serve it, you are leaving a free asset on the table. An email list, a waitlist form, a “coming soon” landing page with a specific offer, these are not marketing tactics. They are proof of demand you can show investors, partners, and distribution channels.
Identify the data loop in your product. Neko’s competitive advantage is not the scanner, it is the longitudinal health record. Every customer interaction you have produces data. Most businesses discard it. Ask: what would it look like to use the data from interaction one to make interaction five ten times more valuable? That is where the recurring revenue lives. The metrics that predict long-term business survival almost always trace back to a product or service that improves over time with usage.
Pick a price point that signals quality, then defend it. Neko charges $500 with no insurance, no apology. The price itself communicates: this is worth paying for. In your own business, the instinct when you are early is to discount. Neko’s story is a reminder that premium pricing to the right audience is often more sustainable than fighting for margin at the low end. Building long-term wealth from a business almost always requires protecting your margins from day one.
Neko Health is still early in its U.S. expansion and faces real regulatory hurdles ahead. But the model, the waitlist, the data product, the premium pricing, is a blueprint worth studying regardless of your industry.
Want more playbooks like this one, three times a week, built for operators and founders?
Join Hustler’s Library free here.
Ready to Know Where You Stand?
The Business Journey dashboard maps your exact position across all 13 stages. Track your progress, unlock resources for each step, and build with a framework used by thousands of founders at Hustler's Library.
No credit card required · Takes 3 minutes · Personalized to your stage
